FDA Approves SACUBITRIL AND VALSARTAN — Umedica Laboratories USA Inc.

Umedica Laboratories USA Inc. has received final FDA approval for sacubitril and valsartan under ANDA219946, allowing the company to enter the market for this blockbuster hypertension drug. This entry is expected to intensify generic competition in the cardiovascular space, potentially pressuring biosimilar pricing tiers as volume ramps up next year.